December 29, 2022 10:49 AM EST
FDA+

TG cross­es the fin­ish line in MS, turn­ing U2 com­po­nent in­to stand­alone drug for biotech's sec­ond ap­proval

Paul Schloesser

Associate Editor

TG Ther­a­peu­tics fi­nal­ly got past the FDA and got a new MS drug ap­proved that the com­pa­ny plans to com­mer­cial­ize against gi­ants like Roche’s Ocre­vus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times